Akorn, Inc. (NASDAQ:AKRX), a leading specialty pharmaceutical company, today announced that it has launched Promethazine Hydrochloride and Phenylephrine Hydrochloride Syrup (Promethazine/Phenylephrine) and Promethazine Hydrochloride, Phenylephrine Hydrochloride and Codeine Phosphate Syrup CV (Promethazine/Phenylephrine/Codeine). The launches follow approval of abbreviated new drug applications (ANDAs) for both products from the U.S. Food and Drug Administration (FDA) in December 2014.
The two products complement Akorn’s existing Promethazine formulations which include Promethazine HCl Oral Solution, USP; Promethazine HCl and Codeine Phosphate Syrup CV; and Promethazine HCl and Dextromethorphan HCl Oral Solution. (Original Source)
Shares of Akorn Inc closed yesterday at $38.04. AKRX has a 1-year high of $57.10 and a 1-year low of $33. The stock’s 50-day moving average is $41.72 and its 200-day moving average is $45.08.
Akorn Inc manufactures and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals as well as niche hospital drugs and injectable pharmaceuticals.